Drug with immunotherapy may provide therapeutic opportunity for patients previously treated for kidney and lung cancer
Pegilodecakin, a first-in-class drug currently in clinical trials, has shown positive safety results and may offer a potential new treatment avenue for patients with non-small cell lung cancer (NSCLC) and kidney cancer. The ...
Sep 26, 2019
0
1